← Leaderboards
Radojka Savic
University Of California, San Francisco
$8,230,011
Attributed
$22,216,027
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $8.4M · FY2015–25$10M$7.5M$5M$2.5M$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$22,216,027 · 5
By mechanism
UM1$14,399,999 · 1
R01$6,124,149 · 3
T32$1,691,879 · 1
Top collaborators
- David Alland5 shared
- Anthony Joseph Garcia-Prats5 shared
- Kelly E. Dooley2 shared
- Eric L Nuermberger2 shared
- Dirk Schnappinger2 shared
- Adithya Cattamanchi1 shared
- Iwijn De Vlaminck1 shared
Most similar at University Of California, San Francisco
Same institution · by research overlap
- John Zapata Metcalfe$8,956,853
- Payam Nahid$19,473,523
- Monica Gandhi$27,077,063
- David M Engelthaler$4,210,794
- Jeffery S Cox$28,484,342
Others in their field
Top investigators on “Treatment Protocols”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Judith S. Currier · University Of California Los Angeles$484,283,739
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$386,589,787
- David Heimbrook · Leidos Biomedical Research, Inc.$218,292,493
- Jeffrey P Krischer · University Of South Florida$213,980,993
Research focus
Treatment ProtocolsTuberculosis TreatmentTuberculosisMultidrug-Resistant TuberculosisTreatment DurationRegimenDoseTuberculosis DrugsMoxifloxacinPharmaceutical PreparationsFutureSamplingSeverity Of IllnessToxic EffectTreatment OutcomePharmacokinetic ModelSafetyDrug Resistance In TuberculosisEnsureDrug KineticsTreatment ResponseSuccessRelapseDrug Resistance
Grant awards (16)
Preclinical Design and Clinical Translation of TB Regimens (PReDicTR) Consortium$7,200,000
UM1 · FY2025 · AI · contact PI
Diagnosis of tuberculosis and monitoring of treatment via RNA liquid biopsy$743,651
R01 · FY2025 · AI · contact PI
Clinical Pharmacology, Drug Action and Pharmacogenetics$506,206
T32 · FY2025 · GM · contact PI
Preclinical Design and Clinical Translation of TB Regimens (PReDicTR) Consortium$7,199,999
UM1 · FY2024 · AI · contact PI
Clinical Pharmacology, Drug Action and Pharmacogenetics$534,314
T32 · FY2024 · GM · contact PI
Identifying Optimal Treatment Strategies for Tuberculosis Treatment$724,769
R01 · FY2023 · AI · contact PI
Clinical Pharmacology, Drug Action and Pharmacogenetics$651,359
T32 · FY2023 · GM · contact PI
Identifying Optimal Treatment Strategies for Tuberculosis Treatment$742,896
R01 · FY2022 · AI · contact PI
Identifying Optimal Treatment Strategies for Tuberculosis Treatment$749,427
R01 · FY2021 · AI · contact PI
Identifying Optimal Treatment Strategies for Tuberculosis Treatment$776,254
R01 · FY2020 · AI · contact PI
Identifying Optimal Treatment Strategies for Tuberculosis Treatment$786,787
R01 · FY2019 · AI · contact PI
Optimizing and operationalizing pediatric drug-resistant tuberculosis treatment$299,535
R01 · FY2019 · HD
Optimizing and operationalizing pediatric drug-resistant tuberculosis treatment$311,733
R01 · FY2018 · HD
Optimizing and operationalizing pediatric drug-resistant tuberculosis treatment$319,701
R01 · FY2017 · HD
Optimizing and operationalizing pediatric drug-resistant tuberculosis treatment$325,815
R01 · FY2016 · HD
Optimizing and operationalizing pediatric drug-resistant tuberculosis treatment$343,581
R01 · FY2015 · HD